Related Experiment Videos
Neuroleptic Malignant Syndrome: A Primary Care Perspective
Sanjay Gupta1, Nikhil D Nihalani
1Department of Psychiatry, University of Buffalo, School of Medicine and Biomedical Sciences, Buffalo, N.Y., and the Department of Psychiatry, Olean General Hospital, Olean, N.Y. ; and Strong Memorial Hospital, Rochester, N.Y .
Primary Care Companion to the Journal of Clinical Psychiatry
|October 30, 2004
Summary
Neuroleptic malignant syndrome (NMS) is a rare but serious complication of neuroleptic medication. Primary care physicians must maintain a high suspicion for NMS in patients with unexplained hyperthermia.
Area of Science:
- Pharmacology
- Neurology
- Internal Medicine
Background:
- Neuroleptic agents are increasingly prescribed in primary care.
- Neuroleptic malignant syndrome (NMS) is a rare, potentially fatal complication of neuroleptic therapy.
- NMS can be easily missed in primary care settings if not actively considered.
Purpose of the Study:
- To review the diagnosis and management of NMS.
- To emphasize the importance of recognizing NMS in primary care.
- To guide primary care physicians in identifying and managing NMS.
Main Methods:
- Literature review focusing on case series and available data.
- Synthesis of diagnostic criteria for NMS.
- Outline of management strategies for NMS.
Main Results:
- NMS diagnosis requires a high index of suspicion.
- Hyperthermia in patients on neuroleptics warrants exclusion of NMS.
- Limited prospective data exists, relying heavily on case reports.
Conclusions:
- Primary care physicians must be vigilant for NMS.
- Prompt recognition and management are crucial for patient outcomes.
- Further prospective research is needed to improve understanding and treatment.